The Pharmacopoeia of the People's Republic of China (Chinese Pharmacopoeia, or ChP) is China's official collection of standards for drug development, production, sales, utilization, supervision, and control.
ChP is updated by the Chinese Pharmacopoeia Commission every five years. The latest version is ChP 2020, which cover 5,911 monographs of traditional Chinese medicines, chemical drugs, biologics, and pharmaceutical excipients.
Volume | Content | Number | |
Volume I | Monographs of traditional Chinese medicines (TCMs) | 2,711 | |
Volume II | Monographs of chemical drugs | 2,712 | |
Volume III | General monographs of biological products | 8 | |
General requirements for biological products | 8 | ||
Monographs of biological products | 153 | ||
Volume IV | General chapters | General requirements for preparations | 38 |
General testing methods and other general chapters | 281 | ||
Guidelines | 42 | ||
Monographs of pharmaceutical excipients | 335 | ||
Related Article: China Issues the 2020 Edition of Chinese Pharmacopoeia
In China, all drugs shall comply with the ChP standards to obtain marketing authorization. Therefore, ChemLinked BaiPharm Portal holds this webinar to help drug applicants understand and meet the ChP standards.
